United Therapeutics: the rare-disease cash engine has to outrun concentration risk
United Therapeutics is a profitable rare-disease biotech with an unusually strong cash baseline. The hard question is not whether the company currently earns money; it is whether pulmonary hypertension concentration, lifecycle management and pipeline investmen
Open